Abstract
We have developed ribozymes (Rz) that inhibit BRCA1 expression in order to study the role of this gene in chemosensitivity. Two Rz, targeting positions 358 or 5282 of the BRCA1 mRNA, were cloned into the retroviral vector LXSN and lipofected into the breast cancer cell-line HBL100. We obtained 79–99% inhibition of BRCA1 expression, as determined by real-time quantitative PCR and by Western blotting. Decreased expression of BRCA1 led to sensitivity to the DNA damaging agents cisplatin and etoposide, resistance to the microtubule-interfering agents (MIA) taxol and vincristine. The molecular mechanism of resistance to MIA was investigated further by determining the status of the JNK pathway. We found that JNK1 expression was elevated, while JNK2 expression was decreased in Rz-expressing clones compared to controls. We have quantified the mRNA levels of BRCA1, JNK1, 2, MEK-4, -7 and c-jun after treatment with MIA. Vincristine treatment of control cells resulted in transcriptional repression of BRCA1, while the JNK1, 2, MEK-4, -7 and c-jun genes were induced. In Rz-treated cells, only JNK1 and MEK-4 were expressed and none was induced after MIA treatment. We then studied the phosphorylation of c-jun, a downstream effector of the JNK pathway. We observed a strong increase in phosphorylated c-jun after MIA treatment of the control cells but not in BRCA1-Rz treated cells, suggesting inhibition of the JNK pathway. These results show that the BRCA1-JNK pathway is involved in the cytotoxic response to MIA treatment, and inhibition of BRCA1 leads to transcriptional modifications of the JNK pathway.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Abbott DW, Thompson ME, Robinson-Benion C, Tomlinson G, Jensen RA, Holt JT . 1999 J. Biol. Chem. 274: 18808–18812
Anderson SF, Schlegel BP, Nakajima T, Wolpin ES, Parvin JD . 1998 Nat. Genet. 19: 254–256
Andres JL, Fan S, Turkel GJ, Wang JA, Twu NF, Yuan RQ, Lamszus K, Goldberg ID, Rosen EM . 1998 Oncogene 16: 2229–2241
Chapman MS, Verma IM . 1996 Nature 382: 678–679
Chen J . 2000 Cancer Res. 60: 5037–5039
Chen J, Silver DP, Walpita D, Cantor SB, Gazdar AF, Tomlinson G, Couch FJ, Weber BL, Ashley T, Livingston DM, Scully R . 1998 Mol. Cell. 2: 317–328
Chen JJ, Silver D, Cantor S, Livingston DM, Scully R . 1999 Cancer Res. 59: 1752s–1756s
Chen Y, Farmer AA, Chen CF, Jones DC, Chen PL, Lee WH . 1996 Cancer Res. 56: 3168–3172
Cortez D, Wang Y, Qin J, Elledge SJ . 1999 Science 286: 1162–1166
Fan S, Twu NF, Wang JA, Yuan RQ, Andres J, Goldberg ID, Rosen EM . 1998a Int. J. Cancer 77: 600–609
Fan S, Wang JA, Yuan RQ, Ma YX, Meng Q, Erdos MR, Brody LC, Goldberg ID, Rosen EM . 1998b Oncogene 16: 3069–3082
Forster AC, Symons RH . 1987 Cell 49: 211–220
Fromes Y, Gounon P, Veitia R, Bissery MC, Fellous A . 1996 J. Protein Chem. 15: 377–388
Harkin DP, Bean JM, Miklos D, Song YH, Truong VB, Englert C, Christians FC, Ellisen LW, Maheswaran S, Oliner JD, Haber DA . 1999 Cell 97: 575–586
Hsu LC, White RL . 1998 Proc. Natl. Acad. Sci. USA 95: 12983–12988
Husain A, He G, Venkatraman ES, Spriggs DR . 1998 Cancer Res. 58: 1120–1123
Jaeger JA, Turner DH, Zuker M . 1989 Proc. Natl. Acad. Sci. USA 86: 7706–7710
Lee JS, Collins KM, Brown AL, Lee CH, Chung JH . 2000 Nature 404: 201–204
Lee LF, Li G, Templeton DJ, Ting JP . 1998 J. Biol. Chem. 273: 28253–28260
Li S, Chen PL, Subramanian T, Chinnadurai G, Tomlinson G, Osborne CK, Sharp ZD, Lee WH . 1999 J. Biol. Chem. 274: 11334–11338
Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, Bell R, Rosenthal J, Hussey C, Tran T, McClure M, Frye C, Hattier T, Phelps R, Haugen-Strano A, Katcher H, Yakumo K, Gholami Z, Shaffer D, Stone S, Bayer S, Wray C, Bogden R, Dayananth P, Ward J, Tonin P, Narod S, Bristow PK, Norris FH, Helvering L, Morrison P, Rosteck P, Lai M, Barrett JC, Lewis C, Neuhausen S, Cannon-Albright L, Goldgar D, Wiseman R, Kamb A, Skolnick MH . 1994 Science 266: 66–71
Ouchi T, Monteiro AN, August A, Aaronson SA, Hanafusa H . 1998 Proc. Natl. Acad. Sci. USA 95: 2302–2306
Pao GM, Janknecht R, Ruffner H, Hunter T, Verma IM . 2000 Proc. Natl. Acad. Sci. USA 97: 1020–1025
Rao VN, Shao N, Ahmad M, Reddy ES . 1996 Oncogene 12: 523–528
Rossi JJ . 1999 Chem. Biol. 6: R33–R37
Ruffner DE, Stomo GD, Uhlenbeck OC . 1990 Biochemistry 29: 10695–10702
Ruffner H, Verma IM . 1997 Prod. Natl. Acad. Sci. USA 94: 7138–7143
Schlegel BP, Green VJ, Ladias JA, Parvin JD . 2000 Proc. Natl. Acad. Sci. USA 97: 3148–3153
Scully R, Anderson SF, Chao DM, Wei W, Ye L, Young RA, Livingston DM, Parvin JD . 1997a Proc. Natl. Acad. Sci. USA 94: 5605–5610
Scully R, Chen J, Ochs RL, Keegan K, Hoekstra M, Feunteun J, Livingston DM . 1997b Cell 90: 425–435
Scully R, Chen J, Plug A, Xiao Y, Weaver D, Feunteun J, Ashley T, Livingston DM . 1997c Cell 88: 265–275
Somasundaram K, Zhang H, Zeng YX, Houvras Y, Peng Y, Wu GS, Licht JD, Weber BL, El-Deiry WS . 1997 Nature 389: 187–190
Thangaraju M, Kaufmann SH, Couch FJ . 2000 J. Biol. Chem. 275: 33487–33496
Tomlinson GE, Chen TT, Stastny VA, Virmani AK, Spillman MA, Tonk V, Blum JL, Schneider NR, Wistuba II, Shay JW, Minna JD, Gazdar AF . 1998 Cancer Res. 58: 3237–3242
Uhlenbeck OC . 1987 Nature 328: 596–600
Vaish NK, Kore AR, Eckstein F . 1998 Nucleic Acids Res. 26: 5237–5242
Wang Q, Zhang H, Kajino K, Greene MI . 1998a Oncogene 17: 1939–1948
Wang TH, Popp DM, Wang HS, Saitoh M, Mural JG, Henley DC, Ichijo H, Wimalasena J . 1999 J. Biol. Chem. 274: 8208–8216
Wang TH, Wang HS, Ichijo H, Giannakakou P, Foster JS, Fojo T, Wimalasena J . 1998b J. Biol. Chem. 273: 4928–4936
Wang TH, Wang HS, Soong YK . 2000 Cancer 88: 2619–2628
Welcsh PL, Owens KN, King MC . 2000 Trends Genet. 16: 69–74
Wong AK, Ormonde PA, Pero R, Chen Y, Lian L, Salada G, Berry S, Lawrence Q, Dayananth P, Ha P, Tavtigian SV, Teng DH, Bartel PL . 1998 Oncogene 17: 2279–2285
Xu X, Weaver Z, Linke SP, Li C, Gotay J, Wang XW, Harris CC, Ried T, Deng CX . 1999 Mol. Cell. 3: 389–395
Yu X, Wu LC, Bowcock AM, Aronheim A, Baer R . 1998 J. Biol. Chem. 273: 25388–25392
Zhang CC, Yang JM, Bash-Babula J, White E, Murphy M, Levine AJ, Hait WN . 1999 Cancer Res. 59: 3663–3670
Zhong Q, Chen CF, Li S, Chen Y, Wang CC, Xiao J, Chen PL, Sharp ZD, Lee WH . 1999 Science 285: 747–750
Zuker M . 1989 Science 244: 48–52
Acknowledgements
We thank N Uhrhammer for critically reading the manuscript. S Lafarge and V Sylvain were supported by doctoral fellowships from Association pour la Recherche contre le Cancer, Villejuif, Paris. This work was partly supported by the Ligue Nationale Contre le Cancer and its departmental committees of Puy de Dôme and Cantal.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lafarge, S., Sylvain, V., Ferrara, M. et al. Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway. Oncogene 20, 6597–6606 (2001). https://doi.org/10.1038/sj.onc.1204812
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1204812
Keywords
This article is cited by
-
Cabazitaxel is more active than first-generation taxanes in ABCB1(+) cell lines due to its reduced affinity for P-glycoprotein
Cancer Chemotherapy and Pharmacology (2018)
-
Calmodulin-like protein 3 is an estrogen receptor alpha coregulator for gene expression and drug response in a SNP, estrogen, and SERM-dependent fashion
Breast Cancer Research (2017)
-
Expression of BRCA1, a factor closely associated with relapse-free survival, in patients who underwent neoadjuvant chemotherapy with docetaxel, cisplatin, and fluorouracil for squamous cell carcinoma of the esophagus
Surgery Today (2017)
-
Breast cancer sensitivity to neoadjuvant therapy in BRCA1 and CHEK2 mutation carriers and non-carriers
Breast Cancer Research and Treatment (2014)
-
Prognostic significance of BRCA1, ERCC1, RRM1, and RRM2 in patients with advanced non-small cell lung cancer receiving chemotherapy
Tumor Biology (2014)